Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Sage Therapeutics, Inc. is placed second among them.

Sage Therapeutics, Inc. (NASDAQ:SAGE) known for its FDA-approved postpartum depression drug Zurzuvae, is acquired by Supernus Pharmaceuticals in a deal valued at up to $795 million. The agreement, announced in June 2025, includes $561 million in cash and contingent value rights, aiming to expand Supernus’s neuropsychiatric portfolio while integrating Sage’s CNS discovery platform. The merger is expected to deliver up to $200 million in annual cost synergies and strengthen Supernus’s 2026 financial outlook.

Sage Therapeutics, Inc. (NASDAQ:SAGE) recently saw workforce reductions, with around 338 employees laid off in 2025. Despite the downsizing, the company continues to advance its clinical pipeline, focusing on SAGE-319 for neurodevelopmental disorders, with Phase 1 data expected by late 2025, and SAGE-324, targeting seizures in developmental and epileptic encephalopathies, with updates anticipated mid-year.

Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio

Earlier in 2025, Sage Therapeutics, Inc. (NASDAQ:SAGE) rejected a takeover offer from Biogen, citing undervaluation, signaling its strategic focus on maximizing shareholder value. The company remains committed to positioning Zurzuvae as a first-line therapy for postpartum depression, supported by expanded commercialization efforts including a strengthened sales force and digital marketing campaigns.

While we acknowledge the risk and potential of SAGE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SAGE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.